These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 2988591)

  • 21. Antihypertensive and hemodynamic effects of oxprenolol versus propranolol.
    Ferlinz J; Easthope JL; Hughes D; Siegel J; Tobis J; Aronow WS
    Clin Pharmacol Ther; 1980 Jun; 27(6):733-43. PubMed ID: 6991196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and pharmacological actions of a long-acting formulation of propranolol.
    Ohashi K; Ebihara A; Kondo K; Usami M
    Arzneimittelforschung; 1984; 34(4):507-12. PubMed ID: 6378211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of long-acting propranolol ('Inderal' LA) in the management of elderly hypertensive patients.
    Hamdy C; Tovey D; Baber NS; McAinsh J
    Eur J Clin Pharmacol; 1982; 22(5):379-81. PubMed ID: 7117349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris.
    Thadani U; Davidson C; Singleton W; Taylor SH
    N Engl J Med; 1979 Apr; 300(14):750-5. PubMed ID: 581782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise.
    Bobik A; Jennings GL; Korner PI; Ashley P; Jackman G
    Br J Clin Pharmacol; 1979 Jun; 7(6):545-9. PubMed ID: 465276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of oxprenolol slow release and osmotic release by exercise testing and ambulatory electrocardiographic monitoring in patients with chronic stable angina pectoris.
    Bowles MJ; Khurmi NS; O'Hara MJ; Raftery EB
    Eur J Clin Pharmacol; 1987; 32(2):127-33. PubMed ID: 3556193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of intravenous beta-adrenergic blockade with or without partial agonist activity upon plasma cyclic AMP and catecholamines in healthy subjects.
    Gennari C; Pollavini G; Nami R; Francini G; Bianchini C; Verdecchia P
    Eur J Clin Pharmacol; 1984; 26(6):695-8. PubMed ID: 6149126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration.
    Gregg MR; Jack DB; Smith SR; Kendall MJ
    J Clin Pharm Ther; 1987 Apr; 12(2):91-9. PubMed ID: 3584272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced exercise noradrenaline concentrations during propranolol treatment: a limiting factor in cardiac beta-adrenoceptor blockade.
    Hurwitz GA; Webb JG; Walle T; Gourley LA; Cobb L
    Can J Cardiol; 1988 Sep; 4(6):262-9. PubMed ID: 2846132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study of the activity of beta-adrenoceptor antagonists in man.
    Taylor SH; Thadani U; Davidson C; singleton W; Myint S
    Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):305-6. PubMed ID: 240783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of oxprenolol in normal subjects.
    Mason WD; Winer N
    Clin Pharmacol Ther; 1976 Oct; 20(4):401-12. PubMed ID: 10124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacology of a new beta-adrenoceptor blocking drug, befunolol. Cross-over comparison with propranolol on repeated administration.
    Ebihara A; Tawara K; Oka T; Ofuji T; Kawahara K
    Eur J Clin Pharmacol; 1982; 23(3):189-95. PubMed ID: 6129139
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the adrenergic control of renin release dominant in man?
    Davies R; Slater JD
    Lancet; 1976 Sep; 2(7986):594-6. PubMed ID: 61340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. beta-Adrenoceptor hypersensitivity after stopping oxprenolol: discrepant findings not attributable to methodology.
    Singh H; Rimmer A; Lewis MJ; Henderson AH
    Br J Clin Pharmacol; 1983 Dec; 16(6):722-4. PubMed ID: 6318786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):163S-169S. PubMed ID: 4005118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relation between plasma concentrations and cardiovascular effects of oral oxprenolol in man.
    Brunner L; Imhof P; Jack D
    Eur J Clin Pharmacol; 1975; 8(1):3-9. PubMed ID: 786674
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the effects on renin release of beta adrenergic antagonists with differing properties.
    Weber MA; Stokes GS; Gain JM
    J Clin Invest; 1974 Dec; 54(6):1413-9. PubMed ID: 4154950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.
    Bradbrook ID; Babiker M; Crome P; Gillies HC; Morrison PJ; Rogers HJ; Shotton P
    Br J Clin Pharmacol; 1986 Apr; 21(4):371-6. PubMed ID: 3707811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.
    Wellstein A; Palm D; Pitschner HF; Belz GG
    Eur J Clin Pharmacol; 1985; 29(2):131-47. PubMed ID: 3000793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of the effects of propranolol and oxprenolol on forearm blood flow and skin temperature.
    Vandenburg MJ; Conlon C; Ledingham JM
    Br J Clin Pharmacol; 1981 May; 11(5):485-90. PubMed ID: 7272160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.